GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genflow Biosciences PLC (LSE:GENF) » Definitions » Treasury Stock

Genflow Biosciences (LSE:GENF) Treasury Stock : £0.00 Mil (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Genflow Biosciences Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. Genflow Biosciences's treasury stock for the quarter that ended in Jun. 2024 was £0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.


Genflow Biosciences Treasury Stock Historical Data

The historical data trend for Genflow Biosciences's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genflow Biosciences Treasury Stock Chart

Genflow Biosciences Annual Data
Trend Dec21 Dec22 Dec23
Treasury Stock
- - -

Genflow Biosciences Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Treasury Stock Get a 7-Day Free Trial - - - - -

Genflow Biosciences Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.


Genflow Biosciences Business Description

Traded in Other Exchanges
Address
6 Heddon Street, London, GBR, W1B 4BT
Genflow Biosciences PLC is a preclinical biotechnology company focused on developing innovative biological interventions aimed at tackling the effects of aging, potentially slowing or halting the aging process and reducing the incidence of age-related diseases and thereby increasing life span. The company is also focused on longevity and the development of therapies to counteract the effects of aging and diseases associated with age.

Genflow Biosciences Headlines

No Headlines